Ex-Key CEO Michael Jaharis
Seeking to acquire pharmaceutical products with "immediate marketing opportunities" to build sales force for new company, Kos Pharmaceuticals. Kos has seven products under development, all current compounds with new or improved delivery systems, primarily cardiovascular products. The Miami-based firm expects all seven to be in Phase III trials by end of 1991. Former Key Chief Operating Officer Daniel Bell is president of Kos; ex-Key Product Development Director Dave Bova is VP-R&D. Kos has a 10,000 sq. ft. R&D facility and is also sponsoring research at Tufts University School of Medicine to develop new indications for current drugs. Jaharis is Schering-Plough's largest individual shareholder.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth